Meeting
2019 Genitourinary Cancers Symposium
Hyperprogressive disease in patients with metastatic genitourinary tumors treated with immune checkpoint inhibitors.
Authors
Cristina Suárez
Hospital General Universitari Vall d’Hebron, Barcelona, Spain
Cristina Suárez , Rafael Morales-Barrera , Alonso Garcia-Ruiz , Macarena Gonzalez , Marta Ligero , Claudia Valverde , Cesar Serrano , Joaquin Mateo , Raquel Perez-Lopez , Joan Carles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 448)
DOI
10.1200/JCO.2019.37.7_suppl.448
Abstract #
448
Poster Bd #
J19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
First Author: Christoffer Gebhardt
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Annual Meeting
Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).
First Author: Camila Bragança Xavier